Halozyme Therapeutics (HALO) Superinvestor holders
21 of the superinvestors we track hold Halozyme Therapeutics (HALO) in their latest 13F filings, $1.2B in total.
Summary
The largest holder is Mark Donovan (Boston Partners), with $217M, 0.2% of the portfolio.
In their latest quarter: 3 opened a new position, 7 added, 9 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Mark Donovan Boston Partners |
Added | 2,773,568 | $217M | 0.2% | Q2 2026 |
| Josef Lakonishok LSV Asset Management |
Added | 1,507,085 | $166M | 0.3% | Q3 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 2,006,479 | $157M | 0.1% | Q2 2026 |
| Arrowstreet Capital | Trimmed | 1,704,623 | $133M | 0.1% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 1,653,285 | $129M | 0.1% | Q2 2026 |
| Wasatch Wasatch Global Investors |
New position | 1,049,647 | $116M | 0.9% | Q3 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 785,556 | $61M | 0.0% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | 739,273 | $58M | 0.1% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 479,611 | $38M | 0.1% | Q2 2026 |
| Ray Dalio Bridgewater Associates |
Trimmed | 463,146 | $36M | 0.1% | Q2 2026 |
| Paul Marshall Marshall Wace |
Added | 188,354 | $15M | 0.0% | Q2 2026 |
| Man Group Man Group plc |
Added | 158,770 | $12M | 0.0% | Q2 2026 |
| Eric Marshall Hodges Capital Management |
Trimmed | 132,071 | $10M | 0.7% | Q2 2026 |
| Robert Torray Torray Investment Partners |
Trimmed | 38,540 | $4M | 0.6% | Q3 2026 |
| Brandon Haley Holocene Advisors |
Held | 9,205 | $720,475 | 0.0% | Q2 2026 |
| Fayez Sarofim Fayez Sarofim & Co |
Held | 7,500 | $587,025 | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
Added | 5,072 | $558,000 | 0.0% | Q3 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 6,268 | $490,596 | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
New position | 4,528 | $354,407 | 0.0% | Q2 2026 |
| Alec Litowitz Magnetar Capital |
New position | 4,257 | $333,195 | 0.0% | Q2 2026 |
| Alger Fred Alger Management |
Trimmed | 3,967 | $310,497 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 22 |
| Q1 2026 | 22 |
| Q4 2025 | 23 |
| Q3 2025 | 29 |
| Q2 2025 | 23 |
| Q1 2025 | 23 |
| Q4 2024 | 23 |
| Q3 2024 | 19 |
Questions about Halozyme Therapeutics
Which superinvestors own Halozyme Therapeutics?
21 of the superinvestors we track hold Halozyme Therapeutics (HALO) in their latest 13F filings, $1.2B in total. Mark Donovan, Josef Lakonishok, David Shaw, Arrowstreet Capital, Two Sigma, Wasatch.
Who is the largest superinvestor holder of HALO?
The largest holder is Mark Donovan (Boston Partners), with $217M, 0.2% of the portfolio.
From Halozyme Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.